Your Messages Inbox
Your Article Summary
See Latest ArticlesCell Genesys Announces Tender Offer Results While Continuing to Pursue Strategic Alternatives
Cell Genesys, 06/24/09
Cell Genesys, Inc. reported that over 98% or approximately $67 million aggregate principal amount of its 3.125% convertible bonds were tendered in its previously announced exchange offer. The Company offered to exchange all of the $68.3 million aggregate principal amount of its outstanding 3.125% Convertible Senior Notes due in 2011 at a purchase price for each $1,000 principal amount of $500, plus accrued interest, $140 worth of common stock equal to approximately 221 shares of common stock, and $310 of new 3.125% Convertible Senior Notes due in May 2013.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09
Myriad Genetics Acquires Exclusive Rights to Pancreatic Cancer Gene Patents From Johns Hopkins
Myriad, 10/16/09
Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09
Article Search
Sponsor